Aeterna Zentaris Presents Proof-of-Concept for Disorazol Z Cytotoxic Conjugates, such as AEZS-125, in Ovarian Cancer Mouse Model

     Aeterna Zentaris Presents Proof-of-Concept for Disorazol Z Cytotoxic
 Conjugates, such as AEZS-125, in Ovarian Cancer Mouse Model at ENA Symposium

PR Newswire


QUÉBEC CITY, CANADA, Nov. 8, 2012 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX:AEZ) (the"Company") today presented encouraging
preclinical results for disorazol Z cytotoxic conjugates, such as AEZS-125, in
ovarian cancer. Results showed the compound's high potential for the treatment
of luteinizing hormone-releasing hormone (LHRH) receptor positive tumors. Data
were presented by the Company's Director of Preclinical Development, Babette
Aicher, PhD, during a poster presentation at the 24^th EORTC-NCI-AACR (ENA)
Symposium on "Molecular Targets and Cancer Therapeutics", currently held in
Dublin, Ireland. The study is funded through a grant from the German Ministry
of Education and Research.

Juergen Engel, PhD, Aeterna Zentaris President and CEO stated, "Disorazol Z
cytotoxic conjugates such as AEZS-125, are an extension of our AEZS-108
innovative LHRH receptor targeted platform in oncology. These encouraging
results presented at the ENA Symposium will enable us to select a specific
drug candidate for further preclinical development expected to start in the
first quarter of 2013."


  *All conjugates of D-Lys^6 -LHRH and disorazol Z analyzed, demonstrated
    high potential
    regarding the treatment of LHRH-receptor positive tumors;

  *For all conjugates, including AEZS-125, proof-of-concept could be
    demonstrated in an
    LHRH-receptor positive A2780 ovarian cancer xenograft model;

  *Experiments are currently under way addressing:

       *Correlation of tumor LHRH-receptor expression and treatment efficacy;
       *Evaluation of additional tumor models, such as endometrium and
         triple-negative breast cancer;
       *Assessment of early safety parameters and orientating acute toxicity
         in rodent models.

The poster, "Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a
LHRH-Receptor Targeting Peptide such as AEZS-125, Interfere with Cell Cycle
Progression in Human Cancer Cell Lines and Suppress Tumor Growth in a
LHRH-Receptor Positive Ovarian Cancer Xenograft Model", B. Aicher, T.
Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R. Jansen, R. Mueller,
E.Guenther, M. Teifel, can be viewed through this link.

About Disorazol Z Cytotoxic Conjugates such as AEZS-125

AEZS-125 is a disorazol Z (AEZS-137) cytotoxic conjugate linked to a
Luteinizing Hormone-Releasing Hormone (LHRH)-receptor targeting peptide.
Disorazol Z is a novel natural compound isolated from myxobacterium Sorangium
cellulosumwith outstanding cytotoxic activity. Disorazol Z is a macrocyclic
polyketide which is available via fermentation in high yield and purity.
Besides tubulin binding, disorazol Z has pro-apoptotic properties and arrested
cancer cells in G2 stage of the cell cycle at subnanomolar concentrations.
Disorazol Z is an ideal partner for the formation of cytotoxic conjugates with
peptides and proteins to selectively target cancer cells.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties
that could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the risk that safety and
efficacy data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future results, events
or developments, unless required to do so by a governmental authority or by
applicable law.



Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.